Cambridge, MA · Founded 2020 · Privately Held (backing)
Operator of a biotechnology company intended to build a hypothesis-free drug discovery and diagnostics platform for human health care advancement. Transition Bio is based in Cambridge, MA and was founded in 2020. Its last known valuation is $26.8 million. It has raised $76.5 million across 3 recorded rounds; the latest was a $13.3 million early-stage round in Oct 2024.
Last price · $/share
—
Implied valuation
$26.8M
Total raised
$76.5M
Last round
Early Stage VC
Oct 2024
Cap table — not yet on record
Transition Bio's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Transition Bio with a free account
·Watch Transition Bio: the Monday email on marks, rounds and moves
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Transition Bio's 3 recorded funding rounds.
Transition Bio Cap Table & Share Classes | Premier Alternatives
